Detection and Monitoring of Circulating Tumor HPV DNA in HPV-Associated Sinonasal and Nasopharyngeal Cancers

Naegele, Saskia; Efthymiou, Vasileios; Das, Dipon; Sadow, Peter M.; Richmon, Jeremy D.; Iafrate, A. John; Faden, Daniel L.

doi:10.1001/jamaoto.2022.4107

Cited by 12 publications

(12 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Zupancic and Näsman performed a systematic review and found that 77 of 79 (97.5%) cases of HPV-related multiphenotypic sinonasal carcinoma occurred within the sinonasal cavity with no regional metastasis, while one occurred in the breasts, and one in the tonsils [61] . Additionally, given that approximately one-third of SNSCCs are HPV-associated [62] , circulating HPV DNA (ctHPVDNA) is being investigated as a noninvasive biomarker of disease status both at diagnosis and throughout treatment [63] . Studies have demonstrated that HPV-associated SNSCC may have genotype distributions distinct from HPV+ oropharyngeal carcinoma, with HPV 16 being less common [64] .…”

Section: Pet/ctmentioning

confidence: 99%

Contemporary surveillance of sinonasal malignancy in adults

Sell,

Panara,

Workman

et al. 2024

Mini-invasive Surg

View full text Add to dashboard Cite

Sinonasal malignancies are a unique subset of head and neck cancers that necessitate close monitoring due to high local recurrence rates. Surveillance consists of a combination of endoscopy, imaging, and patient-reported symptomatology, but no standardized surveillance protocols currently exist. Strategies historically have been based on guidelines for other head and neck malignancies; however, the unique anatomical and histologic presentation of sinonasal malignancies presents challenges. This review discusses the literature surrounding the utility of each of the different surveillance modalities and highlights techniques under investigation to aid clinicians in optimizing the surveillance of sinonasal malignancies.

show abstract

Section: Pet/ctmentioning

confidence: 99%

Contemporary surveillance of sinonasal malignancy in adults

Sell,

Panara,

Workman

et al. 2024

Mini-invasive Surg

View full text Add to dashboard Cite

show abstract

“…1,2 For example, the incidence of oropharyngeal cancer has now exceeded that of cervical cancer in the United States, in part due to the rise of HPV-driven pathology. 1,3 HPV-associated head and neck tumors most commonly occur in the oropharynx, with the second most common site being the sinonasal tract. Currently known HPV-driven pathology in the nasopharynx and sinuses includes nasopharyngeal carcinoma (NPC), sinonasal squamous cell carcinoma (SNSCC), sinonasal papillomas, a few subtypes of neuroendocrine carcinomas, among many others.…”

Section: Introductionmentioning

confidence: 99%

Plasma circulating tumor DNA testing in the management of HPV‐associated sinonasal and nasopharyngeal tumors

Im,

Kuan,

Adappa

et al. 2024

Int Forum Allergy Rhinol

View full text Add to dashboard Cite

“…Circulating tumor DNA (ctDNA) has emerged as an accurate real-time biomarker of disease status across most solid tumor types [2][3][4][5][6][7][8] . However, the performance metrics of ctDNA for detecting MRD immediately following surgery remain poorly understood, due to the scarcity of data available, variability in the approaches used, and the difficulty correlating MRD with recurrence when adjuvant treatment is delivered.…”

Section: Introductionmentioning

confidence: 99%

circulating tumor DNA in the immediate post-operative setting

Efthymiou,

Queenan,

Haas

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

BackgroundCirculating tumor DNA (ctDNA) has emerged as an accurate real-time biomarker of disease status across most solid tumor types. Most studies evaluating the utility of ctDNA have focused on time points weeks to months after surgery, which for many cancer types, is significantly later than decision-making time points for adjuvant treatment. In this systematic review, we summarize the state of the literature on the feasibility of using ctDNA as a biomarker in the immediate postoperative period.MethodsWe performed a systematic review evaluating the early kinetics, defined here as three days, of ctDNA in patients who underwent curative-intent surgery across several cancer types.ResultsAmong the 2057 studies identified, we evaluated eight cohort studies with ctDNA levels measured within the first three days after surgery. Across six different cancer types, all studies showed an increased risk of cancer recurrence in patients with a positive early postoperative ctDNA level.DiscussionWhile ctDNA clearance kinetics appear to vary based on tumor type, across all studies-detectable ctDNA after surgery was predictive of recurrence, suggesting early post-operative timepoints could be feasibly used for determining minimal residual disease. However, larger studies need to be performed to better understand the precise kinetics of ctDNA clearance across different cancer types as well as to determine optimal postoperative time points.SynopsisThis systematic review analyzed the use of ctDNA as a biomarker for minimal residual disease detection in the early postoperative setting and found that ctDNA detection within three days after surgery is associated with an increased risk of recurrence.

show abstract

Detection and Monitoring of Circulating Tumor HPV DNA in HPV-Associated Sinonasal and Nasopharyngeal Cancers

Cited by 12 publications

References 8 publications

Contemporary surveillance of sinonasal malignancy in adults

Contemporary surveillance of sinonasal malignancy in adults

Plasma circulating tumor DNA testing in the management of HPV‐associated sinonasal and nasopharyngeal tumors

circulating tumor DNA in the immediate post-operative setting

Contact Info

Product

Resources

About